Innoviva (INVA) Stock Forecast & Price Target

Innoviva is supported by a durable royalty backbone from Breo and Anoro, with meaningful royalty rights expected to generate roughly $1.0B over the next five years and largely flow to the bottom line, while technical barriers and limited Paragraph IV risk help protect that cash flow. Its operating platform is also gaining traction, as 2Q26 U.S. IST revenue rose 26% year over year to $36.6M, WW product sales reached $51.8M, and internally marketed products exceeded $180M in LTM revenue as of March 2026 with 37% growth in 1Q26. Further upside comes from a healthy pipeline of 20 to 30 acquisition opportunities, strategic stakes such as Armata’s 68% ownership, and strong liquidity of $603.1M in cash and equivalents at end-1Q26.

Innoviva is pressured by a weaker royalty base, with $59.8M in royalties down 11% year over year as GSK cited U.S. pricing pressure and softer inhaled-respiratory demand, while consensus estimates for 2026/2027 have already fallen about 6% to 7%. Its growth assets also look uncertain: Zevtera sales are flattish at roughly $0.4M, projections were cut from about $72M to $39M in 2033E, and longer-term royalty revenue estimates were lowered 4% to 9%. The company’s valuation is additionally vulnerable to asset volatility, as Armata shares fell about 28% in 3Q26, implying up to a $65M negative fair-value adjustment, while execution risks around GIAPREZA, NUZOLVENCE, ZEVTERA, and future launches remain elevated.